Practical issues in the treatment of schizophrenia

J 2013

Practical issues in the treatment of schizophrenia

ČEŠKOVÁ, Eva

Basic information

Original name

Practical issues in the treatment of schizophrenia

Authors

ČEŠKOVÁ, Eva (203 Czech Republic, guarantor, belonging to the institution)

Edition

Minerva Psichiatrica, Edizioni Minerva Medica S.p.A. 2013, 0391-1772

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

RIV identification code

RIV/00216224:14740/13:00071043

Organization unit

Central European Institute of Technology

Keywords in English

Evidence-based medicine; Individualized medicine; Schizophrenia

Abstract

V originále

Treatment should be evidence-based, measurement-based, complex (including pharmacotherapy, psychosocial intervention, and physical health care) and individualized (tailored to the patient). The basis of schizophrenia treatment is still pharmacotherapy. The first generation of antipsychotics (FGAs), known as typical APs, was discovered in the 1950s. Most second generation antipsychotics (SGAs), known as atypical APs, have been developed more recently. SGAs present some advantages in the treatment of certain treatment domains. The binding affinity of APs for specific neuroreceptors is associated with the therapeutic effect, but also with adverse events. The choice of AP for the individual patient should be guided by the side effect profile of the drug, patient experience with certain side effects, previous patient response to certain APs (e.g., individualized treatment), and potential interactions with other prescribed medication. There are some special clinical features influencing the choice of AP treatment (negative, cognitive, depressive and catatonic symptoms, agitation, non-adherence, pharmacoresistance). These features are discussed in more details. In the future more targeted therapies will be available, offering and enhance efficacy and hopefully also safety.

Links

ED1.1.00/02.0068, research and development project

Name: CEITEC - central european institute of technology

Citovat

ČEŠKOVÁ, Eva. Practical issues in the treatment of schizophrenia. Minerva Psichiatrica. Edizioni Minerva Medica S.p.A., 2013, vol. 54, No 2, p. 101-113. ISSN 0391-1772.

@article{1159351,
   author = {Češková, Eva},
   article_number = {2},
   keywords = {Evidence-based medicine; Individualized medicine; Schizophrenia},
   language = {eng},
   issn = {0391-1772},
   journal = {Minerva Psichiatrica},
   title = {Practical issues in the treatment of schizophrenia},
   url = {http://www.scopus.com/record/display.url?eid=2-s2.0-84882412314&origin=resultslist&sort=plf-f&src=s&st1=0391-1772&sid=BE8C6718AF3187DA5FA1E89C09808815.kqQeWtawXauCyC8ghhRGJg%3a620&sot=b&sdt=b&sl=15&s=ISSN%280391-1772%29&relpos=1&relpos=1&citeCnt=0&search},
   volume = {54},
   year = {2013}
}

TY  - JOUR
ID  - 1159351
AU  - Češková, Eva
PY  - 2013
TI  - Practical issues in the treatment of schizophrenia
JF  - Minerva Psichiatrica
VL  - 54
IS  - 2
SP  - 101-113
EP  - 101-113
PB  - Edizioni Minerva Medica S.p.A.
SN  - 03911772
KW  - Evidence-based medicine
KW  - Individualized medicine
KW  - Schizophrenia
UR  - http://www.scopus.com/record/display.url?eid=2-s2.0-84882412314&origin=resultslist&sort=plf-f&src=s&st1=0391-1772&sid=BE8C6718AF3187DA5FA1E89C09808815.kqQeWtawXauCyC8ghhRGJg%3a620&sot=b&sdt=b&sl=15&s=ISSN%280391-1772%29&relpos=1&relpos=1&citeCnt=0&search
L2  - http://www.scopus.com/record/display.url?eid=2-s2.0-84882412314&origin=resultslist&sort=plf-f&src=s&st1=0391-1772&sid=BE8C6718AF3187DA5FA1E89C09808815.kqQeWtawXauCyC8ghhRGJg%3a620&sot=b&sdt=b&sl=15&s=ISSN%280391-1772%29&relpos=1&relpos=1&citeCnt=0&search
N2  - Treatment should be evidence-based, measurement-based, complex (including pharmacotherapy, psychosocial intervention, and physical health care) and individualized (tailored to the patient). The basis of schizophrenia treatment is still pharmacotherapy. The first generation of antipsychotics (FGAs), known as typical APs, was discovered in the 1950s. Most second generation antipsychotics (SGAs), known as atypical APs, have been developed more recently. SGAs present some advantages in the treatment of certain treatment domains. The binding affinity of APs for specific neuroreceptors is associated with the therapeutic effect, but also with adverse events. The choice of AP for the individual patient should be guided by the side effect profile of the drug, patient experience with certain side effects, previous patient response to certain APs (e.g., individualized treatment), and potential interactions with other prescribed medication. There are some special clinical features influencing the choice of AP treatment (negative, cognitive, depressive and catatonic symptoms, agitation, non-adherence, pharmacoresistance). These features are discussed in more details. In the future more targeted therapies will be available, offering and enhance efficacy and hopefully also safety.
ER  -

ČEŠKOVÁ, Eva. Practical issues in the treatment of schizophrenia. \textit{Minerva Psichiatrica}. Edizioni Minerva Medica S.p.A., 2013, vol.~54, No~2, p.~101-113. ISSN~0391-1772.

Detailed Information on Publication Record